Pfizer Ziprasidone Labeling Stops Short Of Second-Line Use; QT Effect Noted

Labeling for Pfizer's ziprasidone (Zeldox) recommends that doctors first consider prescribing antipsychotic agents associated with lower rates of QTc prolongation, but stops short of a second-line designation for the drug.